恒瑞医药与翰森制药签署SHR6508项目独家许可协议

Core Viewpoint - Heng Rui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group to license its SHR6508 project, which is currently in Phase III clinical trials for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis [1][2]. Group 1: Licensing Agreement - The company has entered into an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project [1]. - A commercialization service framework agreement has been signed between Chengdu Shengdi Pharmaceutical and Jiangsu Hengrui Pharmaceutical Group, allowing the latter to provide non-exclusive commercialization services for the company's paricalcitol soft capsule product [1]. Group 2: Product Details - SHR6508 is a novel calcium-sensing receptor allosteric modulator aimed at treating secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, currently undergoing Phase III clinical trials [1]. - Paricalcitol is a synthetic vitamin D analog that suppresses parathyroid hormone (PTH) secretion by binding to the vitamin D receptor, thereby lowering serum PTH levels [1]. - The paricalcitol soft capsule is expected to receive approval from the National Medical Products Administration for market launch in November 2025 [1]. Group 3: Company Background - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2].